Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UTS2R | Q9UKP6 | 8/20 | 0.42 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | SLC5A7 | Q9GZV3 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | SLC6A12 | P48065 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4434289 | 0.95 | UTS2R (0.39) | UTS2RCHRM4LMNAGAAHTT | |
| SCHEMBL4434182 | 0.93 | UTS2R (0.39) | UTS2RDRD2 | |
| SCHEMBL4432573 | 0.92 | TNKS (0.38) | UTS2RCHRM4LMNADRD2POLB | |
| SCHEMBL4432781 | 0.92 | NPFFR1 (0.36) | UTS2RLMNAGAAHTTSLC5A7 | |
| SCHEMBL4430180 | 0.90 | UTS2R (0.43) | UTS2RSLC6A2SLC6A4 | |
| SCHEMBL4433536 | 0.89 | UTS2R (0.45) | UTS2RLMNASLC6A2SLC6A4 | |
| SCHEMBL4438280 | 0.89 | UTS2R (0.42) | UTS2RALDH1A1 | |
| SCHEMBL4432591 | 0.89 | UTS2R (0.43) | UTS2RCHRM4HTTDRD2SLC6A2 | |
| SCHEMBL4426624 | 0.89 | UTS2R (0.44) | UTS2RLMNAALDH1A1SLC6A2SLC6A4 | |
| SCHEMBL4440269 | 0.88 | UTS2R (0.41) | UTS2RHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8759342-B2 | Benzo[1,4]oxazin-3-one, benzo[1,4]thiazin-3-one and quinolin-2-one urotensin II receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2014-06-24 | — | — | US | claimed |
| EP-2049120-A1 | UROTENSIN II RECEPTOR ANTAGONISTS | Janssen Pharmaceutica, N.V. (BE) | 2009-04-22 | — | — | EP | claimed |
| US-20080039454-A1 | Urotensin II receptor antagonists | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-02-14 | — | — | US | claimed |
| WO-2008016534-A1 | UROTENSIN II RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-02-07 | — | — | WO | claimed |
| EP-2049120-A1 | UROTENSIN II RECEPTOR ANTAGONISTS | Janssen Pharmaceutica, N.V. (BE) | 2009-04-22 | — | — | EP | disclosed |
| WO-2008016534-A1 | UROTENSIN II RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039454-A1 | Urotensin II receptor antagonists | UTS2R, PLAUR, NTSR2 | UTS2R 1/4885CHRM4 1612/4885LMNA 3971/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.